Human medicines European public assessment report (EPAR): Aimovig, erenumab, Migraine Disorders, Date of authorisation: 26/07/2018, Revision: 2, Status: Authorised
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):